ZIPSOR (diclofenac potassium) by Medica Corp is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2009.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
ZIPSOR is an oral capsule formulation of diclofenac potassium, a nonsteroidal anti-inflammatory drug (NSAID) approved in 2009. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, thereby providing analgesic, anti-inflammatory, and antipyretic effects. The drug is indicated for acute pain management in patients requiring rapid onset of action.
Late-stage lifecycle with minimal Part D volume signals a mature, contracted portfolio requiring defensive positioning rather than growth investment.
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of ZIPSOR, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain
Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain
Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection
Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections
Worked on ZIPSOR at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
ZIPSOR currently shows zero open linked positions, reflecting its mature, contracted status and minimal growth trajectory. Working on this product offers exposure to defensive brand management, generic transition strategy, and market access optimization—valuable expertise but limited long-term career growth potential.